Rajkummar Rao and Mouni Roy starrer Made In China is slated to release on Diwali this year. However, the songs of the film, Odhani, and Sanedo are making a mark during the ongoing festival of Navratri. Both the songs have great music and have a perfect Gujarati flavour to it which gels well with the festival of Navratri.
Talking about both the songs getting a fantastic response, producer Dinesh Vijan said, "With the film being set in Gujarat, we really wanted to do something special this Garba season. It was important to us to represent the culture and music in a way that takes you down nostalgia lane but also gives you something new to groove to. We’re overwhelmed by the response Odhani and Sanedo have received, our digital handles are constantly buzzing with messages and videos from people across the country and we're looking forward to seeing the Garba fire spread far and wide."
In the song Sanedo, we get to see Rajkummar and Mouni doing a couple of Garba steps as well. Talking about it Roy said, "This was my first attempt at Garba. We have a small Garba sequence in one of the scenes in the film as well which was choreographed by Vijay Ganguly and Shruti taught me how to do it. Taking cues from there, Raj and I decided to try our hands at some Garba choreography in Sanedo. Given our love for dance, Mikhil's brief of just having a good time and doing our own thing without directed choreography was like leaving two kids at a candy store. We just went all out. It was so much fun and we enjoyed every bit of it."
Raj added, "I love Garba as a dance form. While shooting for Sanedo, Mikhil's brief to us was to let loose and add our bit to the choreography wherever we wanted. Keeping up with this classic Navratri number, Mouni and I decided to break into our own version of an impromptu Garba!”
Directed by Mikhil Musale, Made In China also stars Paresh Rawal, Boman Irani, and Amyra Dastur.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.